GLP-1 Patient Lead Generation for Clinics and Telehealth
GLP-1 patient acquisition differs from insurance lead generation because the qualifying criteria are clinical and the conversion event is a booked consult rather than a sale. Screening for BMI range, insurance or self-pay status, prior treatment history and state of residence before the lead reaches your intake team is what separates a workable cost per consult from an unworkable one.
What to qualify before the consult
Four screens remove most of the waste. BMI range or the clinical criterion your programme uses determines eligibility at all. Coverage status determines which pathway the patient enters and how the conversation should be framed.
Prior treatment history matters because a patient already on a GLP-1 elsewhere is a transfer, not a new start, and converts differently. And state of residence determines whether you can treat them at all.
Any of these that your vendor does not screen, your intake team screens on the call. That is not free: it is the difference between a team booking consults and a team doing qualification.
Why state residence is the hard filter
Telehealth prescribing is governed state by state, and the rules change. A lead from a state your providers are not licensed in cannot convert regardless of how well qualified it is on every other axis.
This is the most common source of wasted spend in GLP-1 acquisition, because national campaigns generate national volume by default. Insist that state filtering happens before delivery, not after.
TODO(usama): insert the states our GLP-1 programme currently delivers in.
Measuring the right conversion event
Cost per lead is close to meaningless here because the drop-off between form fill and attended consult is large and varies enormously with screening quality. Track cost per booked consult and cost per attended consult separately; the gap between them is a scheduling and reminder problem, not a lead quality problem.
A worked example: if leads cost $40 and 25% book a consult, cost per booked consult is $160. If 60% of those attend, cost per attended consult is roughly $267. Improving attendance from 60% to 80% cuts that to $200 without buying a single extra lead.
TODO(usama): replace the illustrative booking and attendance rates with our observed figures.
How we generate and screen
We run our own campaigns and screen for clinical criteria, coverage status, prior treatment and state before the patient reaches your intake team. Delivery is by live transfer or real-time post.
TODO(usama): insert current cost per lead, monthly volume, and whether we offer live transfer on GLP-1.
See the main [GLP-1 leads](/lead-generation/glp1) page for programme detail and the [lead generation overview](/lead-generation) for how we run the other verticals.
Common questions
- Do you screen for BMI before transfer?
- Yes, against the criterion your programme uses. TODO(usama): confirm the default BMI threshold we screen to and whether it is configurable per client.
- How do you handle patients seeking insurance coverage versus self-pay?
- They are screened and tagged separately, because the intake conversation and the conversion path differ. Mixing them in one funnel makes your conversion reporting meaningless.
- Can you restrict delivery to specific states?
- Yes, and you should insist on it. State filtering before delivery is the single largest source of avoided waste in GLP-1 acquisition.
- What does a realistic cost per attended consult look like?
- It depends on your screening criteria, your states and your attendance rate, so there is no universal number. TODO(usama): insert our observed range if client reporting supports one.
Start a GLP-1 test batch
Tell us the states your providers are licensed in and the clinical criteria you screen to. We will filter to that before anything reaches your intake team.
Last reviewed